REFILE-BRIEF-Astex Pharmaceuticals responds to further misleading claims made by Sarissa Capital

Wed Oct 9, 2013 10:47pm EDT

Oct 9 (Reuters) - Astex Pharmaceuticals Inc : * Says disappointed that Sarissa Capital continues to mislead Astex

stockholders with information that is incomplete * Says $8.50 per share all-cash transaction with Otsuka was in the best

interests of all Astex stockholders * Says no third parties have approached Astex with an interest to acquire the

company * Source text for Eikon * Further company coverage

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.